AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01280942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless Remote Sensor
Description: A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
Study NCT03379974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP Inhalant Product
Description: For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
Study NCT03379974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDAVP Inhalant Product
Description: For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
Study NCT03379974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
Study NCT02218502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound by general gynaecologist
Description: All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
Study NCT02218502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound by an expert ultrasonographist
Description: Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
Study NCT02218502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DW-MRI
Description: Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
Study NCT02218502 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Give blood sample
Description: Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
Study NCT03102710 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
Study NCT03102710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
Study NCT03102710 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lidocaine cream
Description: Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
Study NCT03102710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Description: Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
Study NCT03102710 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Capsaicin cream
Description: Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
Study NCT03102710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Description: Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
Study NCT03102710 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control cream
Description: A neutral cream will be applied on the arm as a control.
Study NCT03102710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control cream
Description: A neutral cream will be applied on the arm as a control.
Study NCT03945942 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Near infrared spectroscopy with INVOS device
Description: somatic and cerebral oximetry by INVOS in pediatric liver transplantation
Study NCT03945942 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Near infrared spectroscopy with Foresight device
Description: somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
Study NCT03347942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
Study NCT03347942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group will also serve the dish of the form, but can serve additional portion without waiting.
Study NCT02921399 — intervention group
Intervention type: OTHER
Intervention: eradication timing
Description: patients who underwent ESD for gastric neoplasms were randomized to receive early (3-5 days) or late (8-9 weeks) H. pylori eradication therapy after ESD.
Study NCT00579189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00579189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00579189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT00579189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT03101436 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil and Red Wine
Description: Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)
Study NCT04476095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT
Description: Active PBMT will be applied using a device with 152 emitters (wavelength - 808 nm; dose - 3000 J; treatment time - 600 s), in the low back region.
Study NCT04476095 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT
Description: The placebo PBMT will be applied using the same device as that of active PBMT but without any emission of therapeutic dose. Moreover, the irradiated site and the irradiation time were the same as that of active PBMT. Patients received a total dose of 0 J in the placebo mode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
Study NCT04589000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Throughout the study, acupressure will be applied to the acupressure group once on the post-op day 0, 2 times on the post-op 1st day, and once on the post-op 2nd day, 4 times in total for 15 minutes.~15 minutes after acupressure application, milk will be expressed for 15 minutes and the amount of milk expressed will be recorded in the milk measurement table.
Study NCT03336450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP615
Description: SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
Study NCT03336450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHOS/SHP615
Description: MHOS/SHP615
Study NCT02401633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO-CPR
Description: CPR provided by bystander with chest-compressions only
Study NCT02401633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S-CPR
Description: CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
Study NCT00910754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
Study NCT00910754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg tablets administered orally twice daily.
Study NCT04536441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultra Brief Online Mindfulness-based Intervention
Description: We adapted and contextualized the original RAIN protocol to local pandemic-induced lockdown situation, with short journaling prompts that engage participants in self-reflection. Journaling is known to be a creative way to engage people in a therapeutic activity which promotes self-awareness (Utley \& Garza, 2011). Creating a visual narration of thoughts, feelings and experiences help individuals make internal experiences more tangible and manageable, especially during these uncertain times.
Study NCT04536441 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group participants were asked to report preventive measures that they have taken to prevent COVID-19, ways that they obtained Movement Control Order news, and things that they wished to do once the Movement Control Order is lifted.
Study NCT06281704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 IV
Description: AK101 will be administered intravenously.
Study NCT06281704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 SC
Description: AK101 will be administered subcutaneously.
Study NCT06281704 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously or intravenously.
Study NCT06281704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 IV/AK101 SC
Description: AK101 will be administered as intravenous infusion at Week8, then subcutaneously every 8 weeks thereafter .
Study NCT02239796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTrac continence stimulators
Description: Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators.
Study NCT02239796 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroTrac continence stimulators
Description: We are using NeuroTrac continence stimulators.
Study NCT03600935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vancouver Clinical Pathway
Description: Vancouver Clinical Pathway
Study NCT02798718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: full-fat milk
Description: intake 250ml full-fat milk per day, do not intake any other dairy products
Study NCT01397552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 10 mg/mL injected into lumbar spine, one level, one injection
Study NCT01397552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone acetate
Description: 80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
Study NCT00859781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-J591
Description: 177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
Study NCT00859781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
Study NCT00859781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoconazole
Description: Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
Study NCT00859781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
Study NCT00859781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
Study NCT00859781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 111In-J591
Description: 111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
Study NCT01716533 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
Study NCT00682617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist, delayed intervention
Description: Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
Study NCT01679197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Study NCT01716533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stool sample collection
Description: Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
Study NCT00990847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol, Salbultamol
Study NCT00990847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procaterol, Salbultamol
Study NCT04663438 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy Drugs, Cancer
Description: Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
Study NCT04059549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartnerCHESS
Description: Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each.
Study NCT04059549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A-CHESS
Description: A-CHESS control group
Study NCT03168256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 2mg
Description: CF101 tablets, 2mg BID for 16 weeks
Study NCT03168256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101 3mg
Description: CF101 tablets, 3mg BID for 16 weeks
Study NCT03168256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast 30mg
Description: Apremilast tablets, 30mg BID for 16 weeks
Study NCT02914249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice (500 mL/d)
Description: Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
Study NCT03168256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets, BID for 16 weeks
Study NCT02989298 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
Study NCT02107079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: swallowing 1 piece, collecting saliva afterwards
Study NCT01872845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin 40mg
Description: Pravastatin 40mg PO daily for 1year from the day of BES implantation
Study NCT01872845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
Study NCT03918941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carey
Description: mobile application
Study NCT03918941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carey
Description: mobile application
Study NCT04079894 — intervention group
Intervention type: OTHER
Intervention: Standard Movement Protocol
Description: Participant walking, cycling and sitting according to a pre-specified protocol.
Study NCT04079894 — intervention group
Intervention type: DEVICE
Intervention: Accerelerometer Monitoring
Description: 7 days of accelerometer monitoring in participants home-environment.
Study NCT03918941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional information
Description: leaflet, internet link and oral information
Study NCT03918941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional information
Description: leaflet, internet link and oral information
Study NCT04432519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dental implant placement
Description: Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
Study NCT03673241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian System
Description: The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
Study NCT04432519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate dental implant placement
Description: Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
Study NCT03913702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
Study NCT03913702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Acetate
Description: 1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
Study NCT02616237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
Study NCT00000251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O
Study NCT00000251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% isoflurane
Study NCT00000251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4% isoflurane